Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial looking at 32P BioSilicon during chemotherapy for advanced pancreatic cancer
This trial looked at treatment for advanced pancreatic cancer using injections of silicon with a radioactive substance attached.
In this trial, researchers were looking at a new treatment called 32P BioSilicon. This is made of small particles of silicon attached to radioactive phosphorus. Doctors injected the silicon particles directly into the tumour. The aim of the treatment was to kill off any cancer cells nearby.
The researchers were testing 2 different doses of 32P BioSilicon. People had this treatment as well as having chemotherapy.
The aims of the trial were to
- See if 32P BioSilicon helped people with advanced pancreatic cancer
- Find the best dose to use
- Learn more about the side effects
Summary of results
The research team found that 32P BioSilicon was well tolerated and safe to give to people with advanced pancreatic cancer.
This trial recruited 6 people. The first 3 people had a low dose of 32P BioSilicon. As there were no serious side effects, the next 3 people had a higher dose.
For all 6 people, their cancer growth was stopped.
There were no complications at the time of giving 32P BioSilicon. During follow up no major side effects were reported.
The research team concluded that 32P BioSilicon is a safe and well tolerated treatment for people with advanced pancreatic cancer.
We have based this summary on information from the team who ran the trial. As far as we are aware, the information they sent us has not been reviewed independently (
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Paul Ross
Experimental Cancer Medicine Centre (ECMC)